Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Nucleos(t)ide analogue discontinuation strategy to achieve the functional cure for chronic hepatitis B? A systematic review and meta-analysis.

Created on 10 Nov 2026

Authors

Mariantonietta Pisaturo, Pierantonio Grimaldi, Lorenzo Onorato, Chiara Cacace, Nicola Coppola

Published in

European journal of internal medicine. Pages 107274. Nov 09, 2026. Epub Nov 09, 2026.

Abstract

Functional cure rate is low during continuous nucleos(t)ide analog (NA) therapy, and therapy suspension has demonstrated interesting off-treatment responses.
A systematic review and meta-analysis to investigate how stable, HBsAg positive-virally suppressed patients would respond to drug discontinuation in terms of HBsAg clearance, clinical remission, virological relapses, alanine-aminotransferases (ALT) flares, and necessity of therapy reintroduction were performed. Included studies were prospective, experimental and observational studies, including data on outcomes after NA discontinuation in HBV DNA negative patients with positive HBsAg, involving at least 20 patients receiving entecavir or tenofovir, published from 2008 to February 2026, written in English language.
A total of 28 papers (4495 patients) were included in the analysis, with low risk of bias: HBsAg clearance rate at 24, 48 and 96 weeks were of 3%, 8% and 11% (95% IC 1-8%, 4-15%, 7-15%) respectively, with low to moderate heterogeneity (I2=58.4%%, 66.5%, 47.3%); according to the HBeAg status at NA introduction, in those HBeAg negative the HBsAg clearance rates were 3%, 8% and 10% at 24, 48 and 96 weeks, respectively, while in those HBeAg positive 2.3 and 3.4% at 24 and 48 weeks, respectively. Overall a higher HBsAg clearance rate (39% at 96 weeks, 95% CI=10-78%, I2=83.3%) was described in patients with HBsAg <100 UI/ml at discontinuation. Treatment reintroduction due to virological and clinical relapse rates were 21%, 12%, and 17% at 24, 48 and 96 weeks, respectively.
These results showed an overall low rate of HBsAg clearance after NA discontinuation, except for the patients with low HBsAg titers at this time. Thus, NA discontinuation must be balanced in the single case for the risk of virological and clinical relapses.

PMID:
43003704
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement